133 related articles for article (PubMed ID: 9708647)
21. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
22. Long-term complications of chemotherapy for germ cell tumours.
Chaudhary UB; Haldas JR
Drugs; 2003; 63(15):1565-77. PubMed ID: 12887263
[TBL] [Abstract][Full Text] [Related]
23. Cerebrovascular accident during cisplatin-based combination chemotherapy of testicular germ cell tumor: an unusual case report.
Azak A; Oksüzoğlu B; Deren T; Oneç BM; Zengin N
Anticancer Drugs; 2008 Jan; 19(1):97-8. PubMed ID: 18043135
[TBL] [Abstract][Full Text] [Related]
24. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.
Dunn TA; Schmoll HJ; Grünwald V; Bokemeyer C; Casper J
Invest New Drugs; 1997; 15(2):109-14. PubMed ID: 9220289
[TBL] [Abstract][Full Text] [Related]
25. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.
Hollender A; Stenwig EA; Ous S; Fosså SD
Eur Urol; 1997; 31(2):141-7. PubMed ID: 9076455
[TBL] [Abstract][Full Text] [Related]
26. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
[TBL] [Abstract][Full Text] [Related]
27. Optimal number of chemotherapy courses in advanced nonseminomatous testicular carcinoma.
Kennedy BJ; Torkelson J; Fraley EE
Am J Clin Oncol; 1995 Dec; 18(6):463-8. PubMed ID: 8526185
[TBL] [Abstract][Full Text] [Related]
28. Ifosfamide in the treatment of germ cell tumors.
Nichols CR
Semin Oncol; 1996 Jun; 23(3 Suppl 6):65-73. PubMed ID: 8677452
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemotherapy in poor-risk germ-cell tumors.
Srinivas S
Oncology (Williston Park); 2000 Oct; 14(10):1419-23; discussion 1427-30, 1433-4. PubMed ID: 11098508
[TBL] [Abstract][Full Text] [Related]
30. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer.
Brennemann W; Stoffel-Wagner B; Helmers A; Mezger J; Jäger N; Klingmüller D
J Urol; 1997 Sep; 158(3 Pt 1):844-50. PubMed ID: 9258096
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
Culine S; Theodore C; Farhat F; Bekradda M; Terrier-Lacombe MJ; Droz JP
J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
[TBL] [Abstract][Full Text] [Related]
32. Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience.
Muramaki M; Hara I; Miyake H; Yamada Y; Kawabata G; Kamidono S
Int J Urol; 2004 Sep; 11(9):768-73. PubMed ID: 15379942
[TBL] [Abstract][Full Text] [Related]
33. Testicular germ cell tumors: molecular understanding and clinical implications.
Lutzker SG; Barnard NJ
Mol Med Today; 1998 Sep; 4(9):404-11. PubMed ID: 9791864
[TBL] [Abstract][Full Text] [Related]
34. [Rescue chemotherapy in testicular germ cell tumors].
Salazar Soler R; Maroto Rey P; Solà Rocabert C; López López JJ
Arch Esp Urol; 2000; 53(6):554-64. PubMed ID: 11002524
[TBL] [Abstract][Full Text] [Related]
35. Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours.
di Pietro A; Vries EG; Gietema JA; Spierings DC; de Jong S
Int J Biochem Cell Biol; 2005 Dec; 37(12):2437-56. PubMed ID: 16099193
[TBL] [Abstract][Full Text] [Related]
36. Contralateral testicular cancer in spite of TIN-negative double biopsies and interval cisplatin chemotherapy.
Souchon R; Gertenbach U; Dieckmann KP; Hahn E; Ruwe M; Stambolis C; Loy V; Classen J
Strahlenther Onkol; 2006 May; 182(5):289-92. PubMed ID: 16673063
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab.
Kollmannsberger C; Pressler H; Mayer F; Kanz L; Bokemeyer C
Ann Oncol; 1999 Nov; 10(11):1393-4. PubMed ID: 10631474
[No Abstract] [Full Text] [Related]
38. Chemotherapy for good-risk germ-cell tumors.
Ryan CJ; Bajorin DF
Semin Urol Oncol; 2002 Nov; 20(4):244-50. PubMed ID: 12489057
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA
Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816
[TBL] [Abstract][Full Text] [Related]
40. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
